HOWL News and Press, Werewolf Therapeutics Inc. From 01/10/23

Healthcare and life sciences focused investment management firm RA Capital along with its managing partners Peter Kolchinsky and Rajeev Shah have raised their active stake in cancer-focused biopharma Werewolf Therapeutics ( NASDAQ: HOWL ). RA Capital Management, Peter Kolchinsky and R...

Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q3 GAAP EPS of -$0.40 beats by $0.20 . Revenue of $4.97M beats by $0.9M . As of September 30, 2022, cash and cash equivalents decreased to $140.5 million, compared to $157.5 million as of December 31, 2...

- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics - - Preclinical data supports the development of WTX-330, Werewolf’s product candidate, for the potential treatment ...

Dosed first patient in Phase 1/1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in advanced solid tumors; initial data anticipated in the fourth quarter of 2023 - FDA granted clearance of investigational new drug (IND) a...

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bo...

Summary Two new Breakout Stocks for Week 37 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +117.7% YTD. This week two picks beat 10% gains in less than week with top gains in PRCT +25.7% and TUSK +10.5% with VZIO at +9.1%...

WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the b...

- First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE™ therapeutics developed by Werewolf - WTX-124 is designed to target delivery of a highly potent , wild-type IL-2 cytokine to the tumor microenvironment WATERTOWN, ...

The following slide deck was published by Werewolf Therapeutics, Inc. in conjunction with this event. For further details see: Werewolf Therapeutics (HOWL) Investor Presentation - Slideshow

Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.53 misses by $0.11 . Revenue of $4.15M. As of June 30, 2022, cash and cash equivalents were $145.7 million, compared to $157.5 million as of December 31, 2021. For further details s...